Business Wire

VA-CTA

Share
CTA Foundation Announces CES Eureka Park Accessibility Contest Winners

The Consumer Technology Association (CTA)™ Foundation , a national foundation with the mission to link seniors and people with disabilities with technologies to enhance their lives, is proud to announce the winners of the second annual Eureka Park Accessibility Contest: ActiveProtective , Aira , Bansen Labs , BLITAB and KinTrans . The CTA Foundation partnered with Extreme Tech Challenge to collect entries from over 300 startups from around the world. Each winner will receive a booth in Eureka Park during CES® 2017 and a $2,500 cash prize. CES, the gathering place for the global technology industry, runs Jan. 5-8, 2017 in Las Vegas, NV.

“We look forward to witnessing new technologies that provide tools for seniors and people with disabilities, as well as their caregivers, that enable more healthy and independent lives,” said Stephen Ewell, executive director of the CTA Foundation. “Accessibility technology is truly changing lives for the better and will be front and center at CES 2017.”

The winners of the CTA Foundation contest were selected among emerging Eureka Park eligible startups for their innovations that have the potential for a positive impact on older adults and people with disabilities:

  • ActiveProtective: Wearable belt that deploys an airbag when a fall is detected to help prevent hip fractures in older adults.
  • Aira: Platform that connects blind and low vision individuals with certified virtual agents through wearable devices to assist navigation in everyday life.
  • Bansen Labs: First universal adapter that enables individuals to connect their assistive devices to their favorite technologies.
  • BLITAB: The world’s first tactile braille tablet that can display an entire page at once without any mechanical elements.
  • KinTrans: Sign language translation software designed to provide effective communication between sign language users and those who use spoken language.

The Accessibility Marketplace is the premier marketplace to see how accessible technology is providing tools for individuals with disabilities to live healthy and independent lives. Building on last year’s successful inauguration, the marketplace will see a 50 percent increase in the number of exhibiting companies and return to the 2nd level of the Sands Expo Center in Tech West.

This year’s honorees in the Accessible Tech category of the Innovation Awards - an annual competition honoring outstanding design and engineering in consumer technology products - include Aipoly Vision , Open Sesame! , ReSound ENZO2 , Segina Cellion and 3dRudder . Additionally, there will be two CTA Foundation sponsored conference tracks focused on Accessibility, including Why Accessibility Matters to Tech Leaders and Autonomous Vehicles will Aid Independent Living .

To learn more about the CTA Foundation visit www.CTAFoundation.tech .

Note to Editors: The official name of the global technology event is “CES ® .” Please do not use “Consumer Electronics Show” or “International CES” to refer to the event.

Please note updated CES security measures on CES.tech , including bag check points, bag restrictions and exceptions and badge pickup locations for CES 2017.

About the Consumer Technology Association (CTA) Foundation

The CTA Foundation, a public, national foundation affiliated with the Consumer Technology Association (CTA)™, was launched in 2012 with the mission to link seniors and people with disabilities with technologies to enhance their lives. The foundation strategically supports programs that affect these communities and facilitates dialog between industry, consumers, government, advocacy groups and other key stakeholders. For more information visit CTAFoundation.tech

About Consumer Technology Association:

Consumer Technology Association (CTA)TM , is the trade association representing the $287 billion U.S. consumer technology industry. More than 2,200 companies – 80 percent are small businesses and startups; others are among the world’s best known brands – enjoy the benefits of CTA membership including policy advocacy, market research, technical education, industry promotion, standards development and the fostering of business and strategic relationships. The Consumer Technology Association also owns and produces CES® – the world’s gathering place for all who thrive on the business of consumer technologies. Profits from CES are reinvested into CTA’s industry services.

About CES:

CES is the world’s gathering place for all who thrive on the business of consumer technologies. It has served as the proving ground for innovators and breakthrough technologies for 50 years—the global stage where next-generation innovations are introduced to the marketplace. As the largest hands-on event of its kind, CES features all aspects of the industry. Owned and produced by the Consumer Technology Association (CTA)TM , it attracts the world’s business leaders and pioneering thinkers. Check out CES video highlights . Follow CES online at CES.tech and on social .

UPCOMING EVENTS

  • CES Unveiled Las Vegas
    January 3, Las Vegas, NV
  • CES 2017 – Register
    January 5-8, Las Vegas, NV
  • Winter Break
    March 9-12, Snowmass, CO
  • CES Asia 2017
    June 7-9, Shanghai, China
  • CEO Summit
    June 21-24, Amalfi Coast, Italy

Contact:

Consumer Technology Association
Danielle Cassagnol, 703-907-5253
dcassagnol@CTA.tech
www.CTA.tech
or
Elliot Grimm, 703-907-5240
egrimm@CTA.tech

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye